Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth of its diabetes and obesity care treatments, Lilly has also secured some major wins from the Food and Drug Administration (FDA), including approval for both its Alzheimer's disease candidate and eczema drug.While it looks like Lilly may be entering yet a new growth period, there's a lingering competitive threat looming in the background -- and I'm not talking about Novo Nordisk.Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage pharma company that's been eyeing the weight loss market for some time now. During its third-quarter earnings call a few weeks ago, Viking's management revealed some interesting information -- and if I were an executive at Lilly, I'd be listening closely.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool